Theospirex 300 mg retard Uses

How old is patient?
sponsored

What is Theospirex 300 mg retard?

Theospirex 300 mg retard injection is used together with other medicines to treat the acute symptoms of asthma, bronchitis, emphysema, and other lung diseases in a hospital setting.

Theospirex 300 mg retard belongs to a group of medicines known as bronchodilators. Bronchodilators are medicines that relax the muscles in the bronchial tubes (air passages) of the lungs. They relieve cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes.

Theospirex 300 mg retard is available only with your doctor's prescription.

Theospirex 300 mg retard indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Oral

Acute bronchospasm

Adult: Patients not taking Theospirex 300 mg retard or other xanthine medication: Loading dose: 5 mg/kg.

Child: ≥1 yr Same as adult dose.

Elderly: Lower doses should be used.

Hepatic impairment: Reduce dose.

Oral

Chronic bronchospasm

Adult: 300-1,000 mg in divided doses 6-8 hrly. As modified-release preparation: 175-500 mg 12 hrly.

Child: <6 yr Not recommended; 6-12 yr 20-35 kg: 120-250 mg bid; >12 yr 250-500 mg bid.

Elderly: Lower doses should be used.

Hepatic impairment: Reduce dose.

Intravenous

Acute severe bronchospasm

Adult: Patients not taking Theospirex 300 mg retard or other xanthine medication: Loading dose: 4-5 mg/kg by infusion over 20-30 min. Maintenance dose: 0.4-0.6 mg/kg/hr.

Child: Patients not taking Theospirex 300 mg retard or other xanthine medication: Loading dose: 4-5 mg/kg by infusion over 20-30 min. Maintenance dose: 1-9 yr Initially, 0.8-1 mg/kg/hr; >9-12 yr Initially, 0.7-0.77 mg/kg/hr.

Elderly: Lower doses should be used.

Hepatic impairment: Reduce dose.

Incompatibility: Y-site: Cefepime, hetastarch in normal saline, phenytoin, ceftazidime. Syringe: Ceftriaxone.

Special Populations: Reduce dose in patients w/ cor pulmonale, heart failure, liver disease and fever. Smokers and those who consume alcohol may require higher maintenance dose.

How should I use Theospirex 300 mg retard?

Use Theospirex 300 mg retard sustained-release capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Theospirex 300 mg retard sustained-release capsules.

Uses of Theospirex 300 mg retard in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Use: Labeled Indications

Reversible airflow obstruction:

Oral: Treatment of symptoms and reversible airflow obstruction associated with chronic asthma, or other chronic lung diseases (eg, emphysema, chronic bronchitis).

Injection: Treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (eg, chronic bronchitis, emphysema) as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids. Guideline recommendations:

Guideline recommendations:

Asthma: The 2019 Global Initiative for Asthma Guidelines (GINA) and the 2007 National Heart, Lung and Blood Institute Asthma Guidelines recommends against Theospirex 300 mg retard as a long-term control medication for asthma in children ≤5 years of age. Additionally, GINA guidelines do not recommend Theospirex 300 mg retard for asthma in children 6 to 11 years of age.

Oral Theospirex 300 mg retard is a potential alternative option (not preferred) in adolescents and adults as a long-term control medication in mild asthma or as an add-on long-term control medication in moderate to severe asthma; however, a stepwise approach using inhaled corticosteroids (+/- inhaled long-acting beta agonists depending on asthma severity) is preferred to Theospirex 300 mg retard due to efficacy concerns and potential for adverse events (GINA 2019). Both guidelines recommend against Theospirex 300 mg retard for the treatment of asthma exacerbations due to poor efficacy and safety concerns (GINA 2019; NAEPP 2007).

COPD: Based on the Global Initiative for Chronic Obstructive Lung Disease Guidelines (2019), use of Theospirex 300 mg retard in patients with COPD is controversial and lacks data. Theospirex 300 mg retard may favorably impact functional impairment in COPD patients, but exact effects are unclear. Studies that demonstrated improvement were done with slow-release preparations. Theospirex 300 mg retard is not a preferred agent for COPD exacerbations due to its potential for toxicity.

Off Label Uses

Bradycardia, heart transplantation

Data from small observational studies suggest that Theospirex 300 mg retard may be beneficial for the treatment of bradycardia following heart transplantation.

Theospirex 300 mg retard description

sponsored

Theospirex 300 mg retard is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Theospirex 300 mg retard is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Theospirex 300 mg retard is a homologue of phenethylamine.

Theospirex 300 mg retard dosage

General Considerations

Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ®, like other extended-release Theospirex 300 mg retard products, is intended for patients with relatively continuous or recurring symptoms who have a need to maintain therapeutic serum levels of Theospirex 300 mg retard. It is not intended for patients experiencing an acute episode of bronchospasm (associated with asthma, chronic bronchitis, or emphysema). Such patients require rapid relief of symptoms and should be treated with an immediate-release or intravenous Theospirex 300 mg retard preparation (or other bronchodilators) and not with extended-release products.

Patients who metabolize Theospirex 300 mg retard at a normal or slow rate are reasonable candidates for once-daily dosing with Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ®. Patients who metabolize Theospirex 300 mg retard rapidly (e.g., the young, smokers, and some nonsmoking adults) and who have symptoms repeatedly at the end of a dosing interval, will require either increased doses given once a day or preferably, are likely to be better controlled by a schedule of twice-daily dosing. Those patients who require increased daily doses are more likely to experience relatively wide peak-trough differences and may be candidates for twice-a-day dosing with Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ®.

Patients should be instructed to take this medication each morning at approximately the same time and not to exceed the prescribed dose.

Recent studies suggest that dosing of extended-release Theospirex 300 mg retard products at night (after the evening meal) results in serum concentrations of Theospirex 300 mg retard which are not identical to those recorded during waking hours and may be characterized by early trough and delayed peak levels. This appears to occur whether the drug is given as an immediate-release, extended-release, or intravenous product. To avoid this phenomenon when two doses per day are prescribed, it is recommended that the second dose be given 10 to 12 hours after the morning dose and before the evening meal.

Food and posture, along with changes associated with circadian rhythm, may influence the rate of absorption and/or clearance rates of Theospirex 300 mg retard from extended-release dosage forms administered at night. The exact relationship of these and other factors to nighttime serum concentrations and the clinical significance of such findings require additional study. Therefore, it is not recommended that

Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ® (when used as a once-a-day product) be administered at night.

Patients who require a relatively high dose of Theospirex 300 mg retard (i.e., a dose equal to or greater than 900 mg or 13 mg/kg, whichever is less) should not take Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ® less than 1 hour before a high-fat-content meal since this may result in a significant increase in peak serum level and in the extent of absorption of Theospirex 300 mg retard as compared to administration in the fasted state.

The steady-state peak serum Theospirex 300 mg retard concentration is a function of the dose, the dosing interval, and the rate of Theospirex 300 mg retard absorption and clearance in the individual patient. Because of marked individual differences in the rate of Theospirex 300 mg retard clearance, the dose required to achieve a peak serum Theospirex 300 mg retard concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter Theospirex 300 mg retard clearance (e.g., 400-1600 mg/day in adults < 60 years old and 10-36 mg/kg/day in children 1-9 years old). For a given population there is no single Theospirex 300 mg retard dose that will provide both safe and effective serum concentrations for all patients. Administration of the median Theospirex 300 mg retard dose required to achieve a therapeutic serum Theospirex 300 mg retard concentration in a given population may result in either sub-therapeutic or potentially toxic serum Theospirex 300 mg retard concentrations in individual patients. For example, at a dose of 900 mg/day in adults < 60 years or 22 mg/kg/day in children 1-9 years, the steady-state peak serum Theospirex 300 mg retard concentration will be < 10 mcg/mL in about 30% of patients, 10-20 mcg/mL in about 50% and 20-30 mcg/mL in about 20% of patients. The dose of Theospirex 300 mg retard must be individualized on the basis of peak serum Theospirex 300 mg retard concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.

Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments. Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum Theospirex 300 mg retard concentrations to reach the new steady state. Dosage adjustment should be guided by serum Theospirex 300 mg retard concentration measurement. Health care providers should instruct patients and care givers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage.

If the patient's symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements, serum Theospirex 300 mg retard concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum Theospirex 300 mg retard concentrations should be monitored at frequent intervals, e.g., every 24 hours.

Theospirex 300 mg retard distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight. Table V contains Theophylline dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for Theospirex 300 mg retard dosage adjustment based upon serum Theospirex 300 mg retard concentrations. Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum Theospirex 300 mg retard concentration.

Table V. Dosing initiation and titration (as anhydrous Theospirex 300 mg retard).*

A. Children (12-15 years) and adults (16-60 years) without risk factors for impaired clearance.
Titration Step Children < 45 kg Children > 45 kg and adults
1. Starting Dosage 12-14 mg/kg/day up to a maximum of 300 mg/day divided Q 24 hrs* 300-400 mg/day Dose reduction and/or serum Theospirex 300 mg retard concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce Theospirex 300 mg retard clearance occur (e.g., sustained fever), or a drug that interacts with Theospirex 300 mg retard is added or discontinued.

How supplied

Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ® (Theospirex 300 mg retard anhydrous) is supplied in extended-release capsules containing 100, 200, 300 or 400 mg of anhydrous Theospirex 300 mg retard.

Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ® 100 mg capsules are yellow-orange and clear, with markings Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule), 100 mg, ucb, and 2832, supplied as:

NDC Number Size
50474-100-01 bottle of 100
Theospirex 300 mg retard® 200 mg capsules are red-orange and clear, with markings Theospirex 300 mg retard, 200 mg, ucb, and 2842, supplied as:
NDC Number Size
50474-200-01 bottle of 100
50474-200-50 bottle of 500
Theospirex 300 mg retard® 300 mg capsules are red and clear, with markings Theospirex 300 mg retard, 300 mg, ucb, and 2852, supplied as:
NDC Number Size
50474-300-01 50474-300-50 bottle of 100 bottle of 500
Theospirex 300 mg retard® 400 mg capsules are pink and clear, with markings Theospirex 300 mg retard, 400 mg, ucb, and 2902, supplied as:
NDC Number Size
50474-400-01 bottle of 100

Storage

Store below 77 °F (25 °C).

FOR MEDICAL INFORMATION Contact: Medical Affairs Department Phone: (800) 477-7877, Fax: (770) 970-8859. Manufactured for: UCB Pharma, Inc. Smyrna, GA 30080. by Pfizer Pharmaceuticals LLC Caguas, PR 00725. 04/2005.

Theospirex 300 mg retard interactions

See also:
What other drugs will affect Theospirex 300 mg retard?

sponsored

Drug/Drug Interactions

Theospirex 300 mg retard interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to Theospirex 300 mg retard or another drug or occurrence of adverse effects without a change in serum Theospirex 300 mg retard concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of Theospirex 300 mg retard clearance is altered by another drug resulting in increased or decreased serum Theospirex 300 mg retard concentrations. Theospirex 300 mg retard only rarely alters the pharmacokinetics of other drugs.

The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with Theospirex 300 mg retard. The information in the “Effect ” column of Table II assumes that the interacting drug is being added to a steady-state Theospirex 300 mg retard regimen. If Theospirex 300 mg retard is being initiated in a patient who is already taking a drug that inhibits Theospirex 300 mg retard clearance (e.g., cimetidine, erythromycin), the dose of Theospirex 300 mg retard required to achieve a therapeutic serum Theospirex 300 mg retard concentration will be smaller. Conversely, if Theospirex 300 mg retard is being initiated in a patient who is already taking a drug that enhances Theospirex 300 mg retard clearance (e.g., rifampin), the dose of Theospirex 300 mg retard required to achieve a therapeutic serum Theospirex 300 mg retard concentration will be larger. Discontinuation of a concomitant drug that increases Theospirex 300 mg retard clearance will result in accumulation of Theospirex 300 mg retard to potentially toxic levels, unless the Theospirex 300 mg retard dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits Theospirex 300 mg retard clearance will result in decreased serum Theospirex 300 mg retard concentrations, unless the Theospirex 300 mg retard dose is appropriately increased.

The drugs listed in Table III have either been documented not to interact with Theospirex 300 mg retard or do not produce a clinically significant interaction (i.e., < 15% change in Theospirex 300 mg retard clearance).

The listing of drugs in Table II is current as of June 2004. The listing of drugs in Table III is current as of January 2, 1996. New interactions are continuously being reported for Theospirex 300 mg retard, especially with new chemical entities. The healthcare professional should not assume that a drug does not interact with Theospirex 300 mg retard if it is not listed in Table II. Before addition of a newly available drug in a patient receiving Theospirex 300 mg retard, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and Theospirex 300 mg retard has been reported.

Table II. Clinically significant drug interactions with Theospirex 300 mg retard*.

Drug Type of Interaction Effect**
Adenosine Theospirex 300 mg retard blocks adenosine receptors. Higher doses of adenosine may be required to achieve desired effect.
Alcohol A single large dose of alcohol (3 mL/kg of whiskey) decreases Theospirex 300 mg retard clearance for up to 24 hours. 30% increase
Allopurinol Decreases Theospirex 300 mg retard clearance at allopurinol doses ≥ 600 mg/day. 25% increase
Aminoglutethimide Increases Theospirex 300 mg retard clearance by induction of microsomal enzyme activity. 25% decrease
Carbamazepine Similar to aminoglutethimide. 30% decrease
Cimetidine Decreases Theospirex 300 mg retard clearance by inhibiting cytochrome P450 1A2. 70% increase
Ciprofloxacin Similar to cimetidine. 40% increase
Clarithromycin Similar to erythromycin. 25% increase
Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while Theospirex 300 mg retard blocks adenosine receptors. Larger diazepam doses may be required to produce desired level of sedation. Discontinuation of Theospirex 300 mg retard without reduction of diazepam dose may result in respiratory depression.
Disulfiram Decreases Theospirex 300 mg retard clearance by inhibiting hydroxylation and demethylation. 50% increase
Enoxacin Similar to cimetidine. 300% increase
Ephedrine Synergistic CNS effects. Increased frequency of nausea, nervousness, and insomnia.
Erythromycin Erythromycin metabolite decreases Theospirex 300 mg retard clearance by inhibiting cytochrome P450 3A3. 35% increase. Erythromycin steady-state serum concentrations decrease by a similar amount.
Estrogen Estrogen containing oral contraceptives decrease Theospirex 300 mg retard clearance in a dose-dependent fashion. The effect of progesterone on Theospirex 300 mg retard clearance is unknown. 30% increase
Flurazepam Similar to diazepam. Similar to diazepam.
Fluvoxamine Similar to cimetidine. Similar to cimetidine
Halothane Halothane sensitizes the myocardium to catecholamines, Theospirex 300 mg retard increases release of endogenous catecholamines. Increased risk of ventricular arrhythmias.
Interferon, human recombinant alpha-A Decreases Theospirex 300 mg retard clearance. 100% increase
Isoproterenol (IV) Increases Theospirex 300 mg retard clearance. 20% decrease
Ketamine Pharmacologic. May lower Theospirex 300 mg retard seizure threshold.
Lithium Theospirex 300 mg retard increases renal lithium clearance. Lithium dose required to achieve a therapeutic serum concentration increased an average of 60%.
Lorazepam Similar to diazepam. Similar to diazepam.
Methotrexate (MTX) Decreases Theospirex 300 mg retard clearance. 20% increase after low dose MTX, higher dose MTX may have a greater effect.
Mexiletine Similar to disulfiram. 80% increase
Midazolam Similar to diazepam. Similar to diazepam.
Moricizine Increases Theospirex 300 mg retard clearance. 25% decrease
Pancuronium Theospirex 300 mg retard may antagonize non-depolarizing neuromuscular blocking effects, possibly due to phosphodiesterase inhibition. Larger dose of pancuronium may be required to achieve neuromuscular blockade
Pentoxifylline Decreases Theospirex 300 mg retard clearance. 30% increase
Phenobarbital (PB) Similar to aminoglutethimide. 25% decrease after two weeks of concurrent PB.
Phenytoin Phenytoin increases Theospirex 300 mg retard clearance by increasing microsomal enzyme activity. Theospirex 300 mg retard decreases phenytoin absorption. Serum Theospirex 300 mg retard and phenytoin concentrations decrease about 40%.
Propafenone Decreases Theospirex 300 mg retard clearance and pharmacologic interaction. 40% increase. Beta blockingeffect may decrease efficacy oftheophylline
Rifampin Increases Theospirex 300 mg retard clearance by increasing cytochrome P450 1A2 and 3A3 activity. 20-40% decrease
St. John's Wort (Hypericum Perforatum) Decrease in Theospirex 300 mg retard plasma concentrations. Higher doses of Theospirex 300 mg retard may be required to achieve desired effect. Stopping St. John's Wort may result in Theospirex 300 mg retard toxicity.
Sulfinpyrazone Increases Theospirex 300 mg retard clearance by increasing demethylation and hydroxylation. Decreases renal clearance of Theospirex 300 mg retard. 20% decrease
Tacrine Similar to cimetidine, also increases renal clearance of Theospirex 300 mg retard. 90% increase
Thiabendazole Decreases Theospirex 300 mg retard clearance. 190% increase
Ticlopidine Decreases Theospirex 300 mg retard clearance. 60% increase
Troleandomycin Similar to erythromycin. 33-100% increase depending on troleandomycin dose.
Verapamil Similar to disulfiram. 20% increase
* Refer to PRECAUTIONS, Drug Interactions for further information regarding table.

** Average effect on steady state Theospirex 300 mg retard concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum Theospirex 300 mg retard concentration than the value listed.

Table III. Drugs that have been documented not to interact with Theospirex 300 mg retard or drugs that produce no clinically significant interaction with Theospirex 300 mg retard.*

albuterol, systemic and inhaled finasteride norfloxacin
hydrocortisone ofloxacin
amoxicillin isoflurane omeprazole
ampicillin, with or without sulbactam isoniazid prednisone, prednisolone
isradipine ranitidine
atenolol influenza vaccine rifabutin
azithromycin ketoconazole roxithromycin
caffeine, dietary ingestion lomefloxacin sorbitol
cefaclor mebendazole (purgative doses do not inhibit Theospirex 300 mg retard absorption)
co-trimoxazole (trimethoprim and sulfamethoxazole) medroxyprogesterone
methylprednisolone
metronidazole sucralfate
diltiazem metoprolol terbutaline,systemic
dirithromycin nadolol terfenadine
enflurane nifedipine tetracycline
famotidine nizatidine tocainide
felodipine
* Refer to PRECAUTIONS: DRUG INTERACTIONS for information regarding table.

Drug/Food Interactions

Taking Theospirex 300 mg retard (Theospirex 300 mg retard anhydrous capsule) ® less than one hour before a high-fat-content meal, such as 8 oz whole milk, 2 fried eggs, 2 bacon strips, 2 oz hashed brown potatoes, and 2 slices of buttered toast (about 985 calories, including approximately 71 g of fat) may result in a significant increase in peak serum level and in the extent of absorption of Theospirex 300 mg retard as compared to administration in the fasted state. In some cases (especially with doses of 900 mg or more taken less than one hour before a high-fat-content meal) serum Theospirex 300 mg retard levels may exceed the 20 mcg/mL level, above which Theospirex 300 mg retard toxicity is more likely to occur.

The Effect of Other Drugs on Theospirex 300 mg retard Serum Concentration Measurements

Most serum Theospirex 300 mg retard assays in clinical use are immunoassays which are specific for Theospirex 300 mg retard. Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum Theospirex 300 mg retard concentration.

Theospirex 300 mg retard side effects

See also:
What are the possible side effects of Theospirex 300 mg retard?

Adverse reactions associated with Theospirex 300 mg retard are generally mild when peak serum Theospirex 300 mg retard concentrations are < 20 mcg/ mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum Theospirex 300 mg retard concentrations exceed 20 mcg/mL, however, Theospirex 300 mg retard produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal. The transient caffeine-like adverse reactions occur in about 50%of patients when Theospirex 300 mg retard therapy is initiated at doses higher than recommended initial doses (e.g., > 300 mg/day in adults and > 12 mg/kg/day in children beyond 1 year of age). During the initiation of Theospirex 300 mg retard therapy, caffeine-like adverse effects may transiently alter patient behavior, especially in school age children, but this response rarely persists. Initiation of Theospirex 300 mg retard therapy at a low dose with subsequent slow titration to a predetermined age-related maximum dose will significantly reduce the frequency of these transient adverse effects. In a small percentage of patients ( < 3%of children and < 10%of adults)the caffeine-like adverse effects persist during maintenance therapy, even at peak serum Theospirex 300 mg retard concentrations within the therapeutic range (i.e., 10-20 mcg/mL). Dosage reduction may alleviate the caffeine-like adverse effects in these patients, however, persistent adverse effects should result in a reevaluation of the need for continued Theospirex 300 mg retard therapy and the potential therapeutic benefit of alternative treatment.

Other adverse reactions that have been reported at serum Theospirex 300 mg retard concentrations < 20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum Theospirex 300 mg retard concentrations ≥ 15 mcg/mL. There have been a few isolated reports of seizures at serum Theospirex 300 mg retard concentrations < 20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum Theospirex 300 mg retard concentrations < 20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum Theospirex 300 mg retard concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum Theospirex 300 mg retard concentrations < 20 mcg/mL have generally been milder than seizures associated with excessive serum Theospirex 300 mg retard concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).

Table IV. Manifestations of Theospirex 300 mg retard toxicity.*

Percentage of Patients Reported With Sign or Symptom
Acute Overdose

(Large Single Ingestion)

Chronic Overdosage

(Multiple Excessive Doses)

Sign/Symptom Study 1

(n=157)

Study 2

(n=14)

Study 1

(n=92)

Study 2

(n=102)

Asymptomatic NR** 0 NR** 6
Gastrointestinal
Vomiting 73 93 30 61
Abdominal Pain NR** 21 NR** 12
Diarrhea NR** 0 NR** 14
Hematemesis NR** 0 NR** 2
Metabolic/Other
Hypokalemia 85 79 44 43
Hyperglycemia 98 NR** 18 NR**
Acid/base disturbance 34 21 9 5
Rhabdomyolysis NR** 7 NR** 0
Cardiovascular
Sinus tachycardia 100 86 100 62
Other supraventricular tachycardias 2 21 12 14
Ventricular premature beats 3 21 10 19
Atrial fibrillation or flutter 1 NR** 12 NR**
Multifocal atrial tachycardia 0 NR** 2 NR**
Ventricular arrhythmias with hemodynamic instability 7 14 40 0
Hypotension/shock NR** 21 NR** 8
Neurologic
Nervousness NR** 64 NR** 21
Tremors 38 29 16 14
Disorientation NR** 7 NR** 11
Seizures 5 14 14 5
Death 3 21 10 4
* These data are derived from two studies in patients with serum Theospirex 300 mg retard concentrations > 30 mcg/mL. In the first study (Study #1 –Shanon, Ann Intern Med 1993; 119: 1161-67), data were prospectively collected from 249 consecutive cases of Theospirex 300 mg retard toxicity referred to a regional poison center for consultation. In the second study (Study #2 –Sessler, Am J Med 1990; 88: 567-76), data were retrospectively collected from 116 cases with serum Theospirex 300 mg retard concentrations > 30 mcg/mL among 6000 blood samples obtained for measurement of serum Theospirex 300 mg retard concentrations in three emergency departments. Differences in the incidence of manifestations of Theospirex 300 mg retard toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48%of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results.

** NR =Not reported in a comparable manner.

Theospirex 300 mg retard contraindications

See also:
What is the most important information I should know about Theospirex 300 mg retard?

Do not take Theospirex 300 mg retard in larger or smaller amounts or for longer than recommended. Theospirex 300 mg retard overdose can occur if you accidentally take too much at one time, or if your daily doses are too high. To be sure you are using the correct dose, your blood will need to be tested often.

Do not start or stop smoking without first talking to your doctor. Smoking changes the way your body uses Theospirex 300 mg retard, and you may need to use a different dose.

Sometimes it is not safe to use certain drugs at the same time. Many drugs can interact with Theospirex 300 mg retard. Tell your doctor about all other medicines you use. Also tell your doctor if you start or stop using any of your other medications.

Stop using Theospirex 300 mg retard and call your doctor at once if you have severe or continued vomiting, rapid heartbeats, confusion, tremors, or seizure.

Active ingredient matches for Theospirex 300 mg retard:

Theophylline in Hungary.


List of Theospirex 300 mg retard substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Theostan 200mg Capsule CR (Sun Pharmaceutical Industries Ltd)$ 0.02
THEOSTAN - CR Modified Release Capsule/ Tablet / 200mg / 10 units (Ranbaxy (Stancare Division))$ 0.21
Theostan CR 200 mg Capsule (Stancare (Ranbaxy Laboratories Ltd))$ 0.02
THEOSTAN CR 200MG CAPSULE 1 strip / 10 capsule crs each (Stancare (Ranbaxy Laboratories Ltd))$ 0.21
200 mg x 10's (Ranbaxy (Stancare))$ 0.20
Theostan-CR 200mg TAB / 10 (Ranbaxy (Stancare))$ 0.20
THEOSTAN-CR tab 200 mg x 10's (Ranbaxy (Stancare))$ 0.20
Theostan-CR 200mg TAB / 10 (Ranbaxy (Stancare))$ 0.20
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 100 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 200 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 300 mg
Theostat 100 mg x 30 Tablet
Theostat 300 mg x 30 Tablet
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 100 mg (Lagamed)
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 200 mg (Lagamed)
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 300 mg (Lagamed)
Theostat 100 mg x 30 Tablet (Lagamed)
Theostat 300 mg x 30 Tablet (Lagamed)
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 100 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 200 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 300 mg
Theostat 100 mg x 30 Tablet
Theostat 300 mg x 30 Tablet
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 100 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 200 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 300 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 100 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 200 mg
Tablet, Prolonged Release; Oral; Theophylline Monohydrate 300 mg
Theotab SR 200 mg Tablet (Talent Laboratories)$ 0.03
Theotabllin 100 ml Syrup (Swiss Medicare Pvt. Ltd.)$ 0.01
Theotabllin 77+23 Tablet (Swiss Medicare Pvt. Ltd.)$ 0.02
Theotabllin 60 ml Syrup (Swiss Medicare Pvt. Ltd.)$ 0.01
Capsule; Oral; Theophylline Anhydrous 100 mg (Cti)
Capsule; Oral; Theophylline Anhydrous 200 mg (Cti)
Capsule; Oral; Theophylline Anhydrous 300 mg (Cti)
Theotas 600 mg Tablet (Tas Med (I) Pvt. Ltd.)$ 0.07

References

  1. DailyMed. "THEOPHYLLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "theophylline". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "theophylline". http://www.drugbank.ca/drugs/DB00277 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Theospirex 300 mg retard are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Theospirex 300 mg retard. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 8 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved